Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lumen Versus Limb: Reassessing the Optimal Revascularization Strategy in Below-the-Knee Interventions.

JACC. Cardiovascular interventions·2026
Same author

Lessons Learned from the Feasibility Phase of the REvascularization CHoices Among Under-Represented Groups Evaluation (RECHARGE) Trial Program.

American heart journal·2026
Same author

Left Ventricular Ejection Fraction Trajectory and Long-Term Outcomes Following Percutaneous Coronary Intervention for Myocardial Infarction.

JACC. Advances·2026
Same author

Marked underutilization of lipoprotein(a) testing in peripheral artery disease: a national analysis of 8.3 million patients.

American journal of preventive cardiology·2026
Same author

Balloon Pulmonary Angioplasty for Treatment of Chronic Thromboembolic Pulmonary Hypertension: Statement From the BPA-CTEPH Alliance.

JACC. Cardiovascular interventions·2026
Same author

CalShock: beyond the shock team, building on California's cardiogenic shock system of care.

Heart failure reviews·2026

Related Experiment Video

Updated: Jul 9, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

Ejection Fraction Improvement Following Contemporary High-Risk Percutaneous Coronary Intervention: RESTORE EF Study

Jason Wollmuth1, Mitul P Patel2, Thom Dahle3

  • 1Providence Heart and Vascular Institute, Portland, Oregon.

Journal of the Society for Cardiovascular Angiography & Interventions
|August 12, 2024
PubMed
Summary

High-risk percutaneous coronary intervention (HRPCI) supported by Impella showed improved left ventricular ejection fraction (LVEF) at 90 days. Complete revascularization further enhanced LVEF improvement in these patients.

Keywords:
Impellacomplete revascularizationhigh-risk percutaneous coronary interventionleft ventricular ejection fractionpercutaneous coronary intervention

More Related Videos

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.3K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.2K

Related Experiment Videos

Last Updated: Jul 9, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.3K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.2K

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Cardiac Surgery

Background:

  • Limited data exists on left ventricular ejection fraction (LVEF) improvement after high-risk percutaneous coronary intervention (HRPCI) with hemodynamic support.
  • Previous reports focused on clinical outcomes, not specifically on LVEF changes in this patient group.

Purpose of the Study:

  • To evaluate the impact of Impella-supported HRPCI on left ventricular function at midterm follow-up.
  • To assess changes in LVEF in an ideal patient cohort undergoing HRPCI with hemodynamic support.

Main Methods:

  • RESTORE EF: A multicenter, retrospective analysis of prospectively collected data.
  • Assessed 90-day LVEF in patients surviving nonemergent HRPCI with Impella support.
  • Secondary endpoints included changes in New York Heart Association (NYHA) and Canadian Cardiovascular Society (CCS) scores.

Main Results:

  • Baseline LVEF improved from 35% to 45% at 90-day follow-up (P < .0001) in 251 patients.
  • Greater LVEF improvement was observed in patients with a residual SYNTAX score of 0.
  • Significant reductions in NYHA class III/IV (62% to 15%) and CCS grade III/IV (72% to 2%) symptoms were noted.

Conclusions:

  • Hemodynamically supported HRPCI shows a significant improvement in 90-day LVEF in an ideal patient cohort.
  • Complete revascularization is associated with greater LVEF improvement.
  • Findings are hypothesis-generating and warrant further investigation in larger studies and randomized trials.